<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03744910</url>
  </required_header>
  <id_info>
    <org_study_id>CSL300_3001 (VKTX01)</org_study_id>
    <nct_id>NCT03744910</nct_id>
  </id_info>
  <brief_title>Interleukin 6 Blockade Modifying Antibody-Mediated Graft Injury and Estimated Glomerular Filtration Rate (eGFR) Decline</brief_title>
  <acronym>IMAGINE</acronym>
  <official_title>A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial investigates whether clazakizumab (an anti-interleukin (IL)-6 monoclonal antibody
      (mAb)) may be beneficial for the treatment of CABMR in recipients of a kidney transplant by
      inhibiting the production of Donor Specific Antibodies (DSA) and re-shaping T cell alloimmune
      responses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-center, randomized, double-blind, parallel-group, placebo-controlled, Phase 3
      trial investigates whether clazakizumab may be beneficial for the treatment of CABMR in
      kidney transplant recipients by inhibiting the production of DSA and re-shaping T cell
      alloimmune responses. Subjects will be administered clazakizumab at a target dose of 12.5 mg
      (or placebo) by SC injection, Q4W for up to 260 weeks (or until graft loss or death). This
      &quot;event driven&quot; trial has been designed to evaluate the benefits of clazakizumab in prolonging
      the time to an all-cause composite allograft loss endpoint (primary endpoint) in patients
      with CABMR.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2019</start_date>
  <completion_date type="Anticipated">April 2028</completion_date>
  <primary_completion_date type="Anticipated">January 2028</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of all cause composite allograft loss</measure>
    <time_frame>Five years</time_frame>
    <description>The aim of this study is to follow enrolled participants until 221 occurrences of all-cause allograft loss, defined as return to dialysis, allograft nephrectomy, re-transplantation, eGFR &lt;15 mL/min/1.73 m2 or death from any cause have been observed. The analysis will be a stratified log rank test of the effect of treatment on all-cause composite allograft loss, with stratification factors of dichotomized baseline eGFR (25-45 mL/min/1.73 m2 versus &gt;45-65 mL/min/1.73 m2), baseline proteinuria, treatment for early (within 6 months of transplant) ABMR rejection episodes (yes/no), and treatment for late (greater than 6 months post transplant) ABMR rejection episodes (yes/no). Surviving subjects without allograft loss will be censored at the time of their last assessment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Antibody-mediated Rejection</condition>
  <arm_group>
    <arm_group_label>Clazakizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>350 subjects will have a 50/50 chance of being randomly assigned to receive a 12.5 mg subcutaneous (SC) injection once every 4 weeks (Q4W). 175 subjects will be treated with clazakizumab for up to 260 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>350 subjects will have a 50/50 chance of being randomly assigned to receive a SC injection of normal saline once every 4 weeks (Q4W). 175 subjects will be treated with normal saline for up to 260 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Clazakizumab</intervention_name>
    <description>Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6</description>
    <arm_group_label>Clazakizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Unless specified otherwise, all eligibility criteria time-intervals are assessed with
        respect to the screening visit. In order to be eligible to participate in the trial, a
        subject must meet all of the following inclusion criteria:

          1. Age 18-70 years.

          2. Living donor/deceased donor kidney transplant recipients ≥6 months from time of
             transplant.

          3. Diagnosis of CABMR (according to Banff 2015 diagnostic criteria) to include all of the
             following:

               -  Biopsy-proven CABMR (i.e., chronic glomerulopathy (cg) &gt;0) with/without C4d
                  staining. Repeat biopsy to be performed if previous biopsy is not within 6 months
                  (+3 weeks) of the start of the screening period. The local pathologist's
                  diagnosis will be reviewed by a central pathologist to confirm eligibility for
                  entry into the study. Subjects without evidence of chronic tissue injury on light
                  microscopy but who have glomerular basement membrane double contours on electron
                  microscopy (cg1a) are eligible.

               -  Positive for HLA DSA (using single-antigen bead-based assays) post-transplant.
                  Local laboratory DSA results will be reviewed by the central HLA reviewer to
                  confirm eligibility for entry into the study. If presence of HLA DSA is confirmed
                  within 6 months (+3 weeks) of the start of the screening period, the test does
                  not need to be repeated for eligibility.

               -  Note: Treatments for ABMR (including CABMR) or TCMR are not allowed within 3
                  months of the start of screening (see Exclusion Criterion 3). If subject has
                  received one of these treatments at any time prior, a repeat biopsy and repeat
                  DSA test must be performed after halting/completing treatment (to show continuing
                  CABMR). At least 2 months ± 2 weeks should elapse from the end of treatment
                  before the repeat biopsy and DSA test can be performed.

          4. Written informed consent obtained from subject (or legally acceptable representative)
             before any trial-related procedures.

        Unless specified otherwise, all exclusion criteria time-intervals are assessed with respect
        to the screening visit. A subject is not eligible if any exclusion criteria are met:

          1. Participant is unable or unwilling to comply with study procedures in the opinion of
             the Investigator.

          2. Multi-organ transplant recipient or cell transplant (islet, bone marrow, stem cell)
             recipient. Note: recipients of multiple previous kidney transplants are allowed.

          3. Treatment for ABMR (including CABMR) or TCMR within 3 months of the start of
             screening.

          4. Received T cell depleting agents (e.g., alemtuzumab, anti-thymocyte globulin) within 3
             months of the start of screening.

          5. Treatment with mTOR inhibitors within 4 weeks of the start of screening.

          6. Biopsy showing pure TCMR or advanced interstitial fibrosis (ci3), advanced tubular
             atrophy (ct3), vascular fibrous intimal thickening (cv3) or other significant causes
             of renal dysfunction (e.g., BKV nephropathy, glomerulonephritis).

          7. Impaired renal function due to disorders in the transplanted allograft (e.g., renal
             artery stenosis, hydronephrosis).

          8. eGFR &lt;25 mL/min/1.73 m2 or &gt;65 mL/min/1.73 m2 (MDRD4).

          9. Nephrotic range proteinuria defined as spot urine albumin creatinine ratio (UACR)
             ≥2,200 mg/g (≥220 mg/mmol). If spot UACR is above defined limits, repeat test on
             separate day to confirm ineligibility (or collect 24-hour urine to confirm nephrotic
             range proteinuria (≥3.0 g/day)).

         10. Pregnant, breastfeeding, or unwillingness to practice adequate contraception (i.e., a
             highly effective or acceptable method of contraception) during the study and for 5
             months after last dose of investigational drug.

         11. History of anaphylaxis or known hypersensitivity to clazakizumab or to any constituent
             of the drug product.

         12. Abnormal LFTs (alanine aminotransferase (ALT)/aspartate aminotransferase
             (AST)/bilirubin &gt;1.5 x upper limit of normal) or other significant liver disease.

         13. History of active tuberculosis (TB).

         14. History of latent TB (e.g., positive QuantiFERON-TB test) without history of active TB
             unless subject has completed a full course of prophylactic treatment.

         15. History of human immunodeficiency virus (HIV) infection or positive for HIV.

         16. Seropositive for hepatitis B surface antigen (HBsAg).

         17. Hepatitis C virus (HCV) RNA positive.

         18. Known EBV mismatch (at time of transplant): donor seropositive, recipient
             seronegative.

         19. History of GI perforation; diverticular disease or diverticulitis (except if disease
             has been fully excised); or inflammatory bowel disease (except fully excised
             ulcerative colitis).

         20. Neutropenia (&lt;1,000/mm3) or thrombocytopenia (&lt;50,000/mm3).

         21. Active infections requiring systemic antimicrobial agents and unresolved prior to
             screening.

         22. History of or current invasive fungal infection or other opportunistic infection,
             including (but not limited to) the following: a nontuberculous mycobacterial
             infection, aspergillosis, pneumocystosis, and toxoplasmosis.

         23. Active viral infections such as BKV, CMV, or EBV based on polymerase chain reaction
             (PCR) testing. Active infection is defined as a test result ≥ lower limit of
             quantification (LLOQ).

         24. Current or recent (within 3 months) participation in an interventional trial.

         25. Administration of a live vaccine within 6 weeks of the start of screening, including
             but not limited to the following:

               -  Adenovirus

               -  Measles, mumps, and rubella

               -  Oral polio

               -  Oral typhoid

               -  Rotavirus

               -  Varicella zoster

               -  Yellow fever

         26. History of alcohol or illicit substance (including marijuana) abuse.

         27. Present or previous (within 3 years) malignancy except for basal cell carcinoma, fully
             excised squamous cell carcinoma of the skin, or non-recurrent (within 5 years)
             cervical carcinoma in-situ.

         28. Presence of a condition or abnormality (i.e., clinically significant endocrine,
             autoimmune, metabolic, neurological, psychiatric/psychological, renal, GI, hepatic,
             and hematological or any other system abnormalities that are uncontrolled with
             standard treatment) that in the opinion of the Investigator would compromise the
             safety or life expectancy of the patient or the quality of the data.

         29. History of intolerance to trimethoprim and/or sulfamethoxazole. This criterion does
             not apply if subject is already taking another suitable Investigator-approved
             alternative for Pneumocystis jiroveci pneumonia (PJP) prophylaxis, or if subject is
             willing to begin taking an Investigator-approved alternative prophylactic therapy at
             least 1 week prior to the Day 1 Baseline visit (Visit 2).

         30. Prior exposure to clazakizumab, TCZ, or other IL-6/IL-6R blockers.

         31. ABO-incompatible transplant recipient.

         32. Severe hypogammaglobulinemia (defined as immunoglobulin G (IgG) &lt;400 mg/dL).

         33. Prior (within 2 years of the start of screening) exposure to proteasome inhibitors
             (e.g., bortezomib).

         34. Active infection with COVID-19:

        34a. Subject not known to have been previously infected with COVID-19 must have a negative
        PCR test during the screening period as near to the Day 1 Baseline visit (Visit 2) as
        possible. If subject is unwell with symptoms suggestive of COVID 19 disease but PCR test is
        negative, other causes for symptoms must be ruled out to determine subject eligibility.

        34b. Subject known to have been previously infected with COVID-19 must meet all of the
        following conditions:

          -  Must be asymptomatic for at least 1 month before the start of screening and have had 2
             negative PCR tests at least 24 hours apart (either prior to or during screening) to
             confirm recovery.

          -  Must be re-established on background immunosuppressants for at least 2 weeks prior to
             the start of screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Registration Coordinator</last_name>
    <phone>610-878-4000</phone>
    <email>clinicaltrials@cslbehring.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>480-342-2536</phone>
    </contact>
    <investigator>
      <last_name>Hasan Khamash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Institute of Renal Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Gripp</last_name>
      <phone>858-637-4600</phone>
    </contact>
    <investigator>
      <last_name>Arman Faravardeh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NU Comprehensive Transplant Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>312-964-0234</phone>
    </contact>
    <investigator>
      <last_name>John Friedewald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center/ Maine Medical Center Research Institute</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>207-396-8184</phone>
    </contact>
    <investigator>
      <last_name>John Vella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>410-328-0303</phone>
    </contact>
    <investigator>
      <last_name>Matthew Weir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>313-916-4596</phone>
    </contact>
    <investigator>
      <last_name>Milagros Samaniego-Picota, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>507-538-9617</phone>
    </contact>
    <investigator>
      <last_name>Carrie Schinstock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Assistant</last_name>
      <phone>402-552-2285</phone>
    </contact>
    <investigator>
      <last_name>Eric Langewisch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>347-671-8217</phone>
    </contact>
    <investigator>
      <last_name>Enver Akalin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-263-3620</phone>
    </contact>
    <investigator>
      <last_name>Infana Soomro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-305-6842</phone>
    </contact>
    <investigator>
      <last_name>David Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>336-716-9353</phone>
    </contact>
    <investigator>
      <last_name>Colleen Jay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>513-558-9965</phone>
    </contact>
    <investigator>
      <last_name>Ervin Woodle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Pennsylvania Transplant Foundation</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>717-251-8765</phone>
    </contact>
    <investigator>
      <last_name>Manpreet Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>843-792-7558</phone>
    </contact>
    <investigator>
      <last_name>Vinaya Rao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Nephrology Clinical Trials</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>615-936-1179</phone>
    </contact>
    <investigator>
      <last_name>Harold Helderman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renal Disease Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>214-366-6133</phone>
    </contact>
    <investigator>
      <last_name>Bernard Fischbach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VCU Health</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>804-382-2243</phone>
    </contact>
    <investigator>
      <last_name>Guarav Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>206-598-1562</phone>
    </contact>
    <investigator>
      <last_name>Nicolae Leca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Medical Research Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>509-474-4302</phone>
    </contact>
    <investigator>
      <last_name>Samer Bani Hani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin School of Medicine and Public Health (UWSMPH)</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Research Coordinator</last_name>
      <phone>608-265-6544</phone>
    </contact>
    <investigator>
      <last_name>Arjang Djamali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Steven Chadban, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WSLHD, Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Coordinator</last_name>
      <phone>61288906848</phone>
    </contact>
    <investigator>
      <last_name>Philip O'Connell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>3176 6325</phone>
    </contact>
    <investigator>
      <last_name>Scott Campbell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>61 8 7074 3077</phone>
    </contact>
    <investigator>
      <last_name>Toby Coates, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Health Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>03 9594 3521</phone>
    </contact>
    <investigator>
      <last_name>William Mulley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3064</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>61393424744</phone>
    </contact>
    <investigator>
      <last_name>Peter Hughes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital - Gordon &amp; Leslie Diamond Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>604 682 2344</phone>
      <phone_ext>64706</phone_ext>
    </contact>
    <investigator>
      <last_name>Olwyn Johnston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital, Providence Health Care, Univ. Of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>604 682 2344</phone>
    </contact>
    <investigator>
      <last_name>John Gill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shared Health Inc. operating as the Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <contact_backup>
      <phone>204-787-8662</phone>
    </contact_backup>
    <investigator>
      <last_name>Peter Nickerson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>902-473-7625</phone>
    </contact>
    <investigator>
      <last_name>Amanda Vinson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>519-685-8500 x 34769</phone>
    </contact>
    <investigator>
      <last_name>Anthony Jevnikar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>514-934-1934 ext 36569</phone>
    </contact>
    <investigator>
      <last_name>Marcelo Cantarovich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Paul's Hospital Foundation</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7M 0Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>306 655 5990</phone>
    </contact>
    <investigator>
      <last_name>Ahmed Shoker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IKEM</name>
      <address>
        <city>Prague</city>
        <zip>14000</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>420261362144</phone>
    </contact>
    <investigator>
      <last_name>Ondrej Viklicky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU GRENOBLE ALPES - Consultation Néphrologie Bureau des ARC (Côté Chartreuse, Rez-de-Chaussée Haut)</name>
      <address>
        <city>Grenoble</city>
        <state>Grenoble Cédex 09</state>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>04 76 76 72 62</phone>
    </contact>
    <investigator>
      <last_name>Lionel Rostaing</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Néphrologie - Pavillon Sainte Venise - CHU de Rouen - Hôpital de Bois Guillaume</name>
      <address>
        <city>Bois-Guillaume</city>
        <zip>76230</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>02 32 88 9152</phone>
    </contact>
    <investigator>
      <last_name>Dominique Bertrand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>33 4 72 11 62 20</phone>
    </contact>
    <investigator>
      <last_name>Emmanuel Morelon, Med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Olivier Aubert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>33 5 61 32 28 94</phone>
    </contact>
    <investigator>
      <last_name>Nassim Kamar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite - Universitaetsmedizin Berlin - Campus Charite Mitte (CCM)</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lead Study Coordinator</last_name>
      <phone>004930 450614183</phone>
    </contact>
    <investigator>
      <last_name>Klemens Budde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem, Klinikai Központ, Auguszta</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>36 30 670 7453</phone>
    </contact>
    <investigator>
      <last_name>Balazs Nemes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Szeged</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>36306599227</phone>
    </contact>
    <investigator>
      <last_name>Gyorgy Lazar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nurse</last_name>
      <phone>31243614761</phone>
    </contact>
    <investigator>
      <last_name>Luuk Hilbrands, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC location AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Co-ordinator</last_name>
      <phone>0031-205661168</phone>
    </contact>
    <investigator>
      <last_name>Frederike Bemelman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31-10-703 46 07</phone>
    </contact>
    <investigator>
      <last_name>Michiel Betjes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMCUtrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00318875 59768</phone>
    </contact>
    <investigator>
      <last_name>Arjan Van Zuilen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>8003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>34932483689</phone>
    </contact>
    <investigator>
      <last_name>Marta Crespo Barrio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>93 274 60 00 ext. 4872</phone>
    </contact>
    <investigator>
      <last_name>Daniel Seron Micas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>34932275400</phone>
      <phone_ext>4408</phone_ext>
    </contact>
    <investigator>
      <last_name>Fritz Diekmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>8907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>34932607385</phone>
    </contact>
    <investigator>
      <last_name>Jose Maria Cruzado Garrit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>976765624</phone>
    </contact>
    <investigator>
      <last_name>Alex Gutierrez Dalmau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Active</keyword>
  <keyword>Antibody-mediated Rejection (AMR)</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

